.
.
.
.
Coronavirus

Pfizer lifts sales forecast by 70 pct for COVID-19 vaccine to $26 billion

Published: Updated:

Pfizer Inc on Tuesday forecast $26 billion in sales of the COVID-19 vaccine this year, an increase of more than 70 percent from its last projection and a reflection of the growing global vaccination drive.

The vaccine, which it co-developed with Germany’s BioNTech SE, generated $3.5 billion in revenue in the first quarter, beating the consensus estimate of $3.28 billion, according to six analysts polled by Refinitiv.

For more coronavirus news, visit our dedicated page.

“Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine –- similar to that of the flu vaccines -– is a likely outcome,” Chief Executive Officer Albert Bourla said in his prepared remarks ahead of the conference call.

For the latest headlines, follow our Google News channel online or via the app.

Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech. The raised goal assumes 1.6 billion vaccine doses will be delivered in the year.

The US drugmaker had previously forecast sales of $15 billion. It now expect to manufacture at least 3 billion doses of the vaccine next year.

The two-dose vaccine has shown an efficacy rate of more than 90 percent in late-stage trials, on par with Moderna Inc’s vaccine but higher than the rates seen from AstraZeneca plc and Johnson & Johnson.

Moderna has forecast $18.4 billion in 2021 sales of its COVID-19 vaccine.

Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.

Shares the company was up 1.5 percent in premarket trading.

Read more:

US FDA expected to approve Pfizer vaccine for teens within week

No safety concerns, heart inflammation reports on Pfizer vaccine: UK regulator

BioNTech expects vaccine trial results for babies, other EMA approvals soon